Soluble B-cell maturation antigen in multiple myeloma

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• B-cell maturation antigen (BCMA) is a key target in multiple myeloma (MM) immunotherapy.
• Approved therapies include antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies targeting BCMA.
• Soluble BCMA (sBCMA) is a truncated form measurable in patient serum.

Purpose of the Study:

• To evaluate the utility of soluble BCMA (sBCMA) as a biomarker in multiple myeloma (MM).
• To assess sBCMA's role in diagnosis, prognostication, and monitoring of MM patients.
• To determine if sBCMA is ready for widespread clinical application in MM management.

Main Methods:

• Quantification of sBCMA in serum/plasma samples from MM patients.
• Utilized methods include electrochemiluminescence, fluorescence, ELISA, and mass spectrometry-based proteomics.
• Reviewed existing literature on sBCMA's clinical utility.

Main Results:

• sBCMA has a short serum half-life and is independent of kidney function.
• sBCMA is a reliable tool for monitoring MM, especially in nonsecretory or oligosecretory disease.
• Studies suggest sBCMA aids in risk stratification, diagnosis, prognostication, and response evaluation.

Conclusions:

• sBCMA demonstrates significant potential as a versatile biomarker in multiple myeloma.
• Its convenience and reliability make it a valuable tool for MM laboratory testing.
• Further validation is needed to confirm its readiness for routine clinical use.